Teva settles indirect purchaser claims in Effexor XR US case for $2.25 million
MLex Summary: Teva Pharmaceuticals agreed to a $2.25 million settlement with indirect purchasers of Effexor XR to resolve allegationst the company unlawfully blocked generic competition for the drug. The deal is...To view the full article, register now.
Already a subscriber? Click here to view full article